Background: Overexpression of proangiogenic vascular endothelial growth factor A family VEGFA xxx is associated with tumor growth and metastasis. The role of the alternatively spliced antiangiogenic family VEGFA xxx b is poorly investigated in head and neck squamous cell carcinomas (HNSCCs). The antiangiogenic isoform binds to bevacizumab and its expression level could influence the treatment response and progression-free survival. In this study, the relative expression of VEGFA xxx and VEGFA 165 
Introduction
Angiogenesis is an essential mechanism for tumor growth and results from genetic and/or environmental alterations. The formation of new vessels is a complex process that involves receptors, cytokines, enzymes and growth factors (Carmeliet et al., 2002) , such as the vascular endothelial growth factor A (VEGFA). In vitro and in vivo experiments have shown that increased expression of VEGFA is associated with tumor growth and metastasis (Harper et al., 2008) .
VEGFA gene consists of eight exons and seven introns with approximately 14 kilobases in length (Houck et al., 1991 , Arcondéguy et al., 2013 . Alternative splicing of exon 8 from pre-mRNA originates two families of protein: 1 VEGFA xxx and VEGFA xxx b, where xxx is the number of amino acids encoded. VEGFA isoforms are generally co-expressed in all tissues and VEGF 165 and VEGFA 165 b are the main isoforms. VEGFA 165 b protein has 96% homology with VEGFA 165 , but it presents different C-terminus amino acid sequence (Eswarappa and Fox, 2015) . Studies have shown that VEGFA 165 b binds to VEGFR2 with the same affinity as VEGF 165 , but does not activate it completely resulting in alteration of the downstream signaling (Cébe-Suarez et al., 2006 , Biselli-Chicote et al., 2012 . This alternative isoform was associated with inhibition of endothelial proliferation, migration and vasodilation (Bates et al., 2002) , and can reduce the physiological angiogenesis and tumor growth (Qiu et al., 2007) , because the isoforms compete for the receptor ligation (Woolard et al., 2004) . Tumors expressing VEGF 165 b grow significantly slowly than tumors expressing VEGF 165 (Woolard et al., 2004) , suggesting that a switch in splicing from VEGF 165 to VEGF 165 b can inhibit the tumor growth.
The regulation of VEGFA xxx and VEGFA xxx b splicing remains unclear. However, it is known that exon splicing depends on the balance of the activity of serine-rich (SR) proteins, such as SRSF1, SRSF5 and SRSF6, in determining the C-terminus region. The splicing factors SRSF1 and SRSF5 support the proximal splicing site selection of the VEGFA pre-mRNA, leading to VEGFA xxx expression, while SRSF6 supports the distal splicing site selection promoting VEGFA xxx b expression (Nowak et al., 2008) . Other important regulators of splicing include some SR protein kinases, such as SRPK1, that phosphorylate serine-arginine domains present in splicing factors (Manley et al., 1996) . SR proteins can be regulated both directly by SR kinase proteins, such as Clk1 and SRPKs, and indirectly by mitogen-activated protein kinase (MAPK) and protein kinase C (PKC). SRPKs phosphorylate SRSF1 favoring the proximal splicing and Clk1 results in phosphorylation of SRSF1, SRSF6 and SRSF5 (Prasad et al., 1999 , Lai et al., 2003 .
Since most previous studies on HNSCC have not distinguished between proangiogenic and antiangiogenic isoforms and there are insufficient data for understanding the role of VEGF 165 b isoform in HNSCC, mainly in oral tumor, we aimed to evaluate the expression of VEGFA xxx and VEGFA 165 b isoforms in HNSCC, and investigate alternative splicing of VEGFA in this tumor type.
Materials and Methods

Patients and tissue samples
The study protocol was approved by Institutional Ethics Committee. Informed consent was obtained from the participants of the study. Fresh tissue from 52 HNSCC and 26 adjacent non-tumor tissues were collected from 1998 to 2000 at the Head and Neck Surgery Service, Arnaldo Vieira de Carvalho Cancer Institute, Sao Paulo, Brazil, and from 2007 to 2012 at the Otolaryngology and Head and Neck Surgery Service, Hospital de Base / FAMERP, Sao Jose do Rio Preto, Brazil. Samples were immediately frozen in liquid nitrogen and stored at -80ºC until processing. Microdissection of the samples was performed in Pathology Laboratory at Hospital de Base. Representative formalin-fixed block from 26 tumor samples and 15 adjacent non-tumor tissues were selected for immunohistochemical staining.
Median age of the patients was 58±11.56 years. Eighty three percent of the patients were smokers, and 68% were alcohol consumers. The study cohort consisted mostly of male patients (72.1%) and the most frequent primary tumor site was the oral cavity (51%) followed by larynx (26%) and pharynx (23%). Twenty-two percent of the patients performed radio and/or chemotherapy. Despite the relationship of Human Papillomavirus (HPV) infection with HNSCC development in some populations, HPV status was not evaluated in our study because the low prevalence of HPV infection in HNSCC in Brazilian population (Ribeiro et al., 2011) . Tumor staging was performed according to the 7th edition of the TNM staging system (Sobin et al., 2010) . T1N0 tumors were classified as stage I; T1N1 and T2N0-1 tumors as stage II; T3N0-1 and T1-3N2 tumors as stage III; and T4N0-3, T1-3N3 and T1-4N0-3M1 as stage IV (Fleming et al., 1997) . For statistical analyses stage I and II tumors were grouped and classified as non-advanced tumors and stage III and IV tumors were classified as advanced tumors. Based on histopathological examination of the surgical specimen, 33% presented nodal metastasis and 56% of the patients had advanced primary tumors.
Quantitative real time PCR
Total RNA was extracted with TRIzol Reagent (Ambion, TX) following manufacturer's instructions. Two micrograms of total RNA were reverse-transcribed using RT-PCR kit (Applied Biosystems, CA). VEGFA xxx and VEGFA 165 b expression in HNSCC and adjacent non-tumor tissues was evaluated using primers that distinguish both families of VEGFA isoform. Primers and probe were designed using Primer Express v.3.0 software (Applied Biosystems, CA) using the VEGFA complementary DNA (cDNA) sequence (GenBank: NM_001171623.1). Primer set and probe used for detection of VEGFA xxx family amplify VEGFA 148 , VEGFA 165 , VEGFA 183 , VEGFA 189 and VEGFA 206 isoforms: forward primer 5' AACACAGACTCGCGTTGCAA 3', reverse primer 5' CGCCTCGGCTTGTCACAT 3' and TaqMan MGB 6-FAM probe 5' AGCTTGAGTTAAACGAAC 3'. Reactions were performed in triplicate in 96 wells plate using 100ng of cDNA, 100 nM of forward primer, 300 nM of reverse primer and 250 nM of probe (Applied Biosystems, CA). The reactions were performed on StepOne Plus Real-Time PCR System (Applied Biosystems, CA) and cycled following manufacturer's instructions.
Foward primer and probe used for VEGFA xxx were also used for VEGFA 165 b (GenBank:NM_001171629.1); however a specific reverse primer to the end of the exon 7 and beginning of the exon 8b was used to detect only the VEGFA 165 b isoform (5' TTCCTGGTGAGAGATCTGCAAGTA 3').
The reactions for VEGFA 165 b quantification were performed using 100 ng of cDNA, 900 nM of forward and reverse primers and 250 nM of probe (Applied Biosystems, CA). Primers and probes sequences for SRSF6, SRSF5, SRSF1 and SRPK1 genes were analyzed using TaqMan Gene Expression Assay (Applied Biosystems, CA).
Raw qPCR data were calculated by StepOne software version 2.0 (Applied Biosystems, CA) after manual adjustment of the basal fluorescence signal and the threshold. Relative gene expression from tumor samples was analyzed using non-tumor samples as calibrator group and TBP and RPLPO as reference genes (Applied Biosystems, CA). Fold change (FC) was calculated by ddCt algorithm.
Immunohistochemistry
Three-micrometer thick sections of formalin-fixed paraffin-embedded tissues were cut and mounted onto silanized glass slides. Sections were dewaxed, rehydrated, (p < 0.0001) was observed in tumor samples as compared to adjacent non-tumor tissues (Table 1 and Figure 1 ). Radio and/or chemotherapy did not change VEGFA xxx and VEGFA 165 b expression in the analyzed casuistic (data not shown). Corroborating gene expression data, immunohistochemistry analyses showed that VEGFA xxx and VEGFA 165 b proteins are significantly (p <0 .0001) overexpressed in tumor samples (75.11% and 63.89% of the stained area, respectively) as compared to non-tumor washed in distilled water and the antigenic retrieval was performed in microwave with sodium citrate (pH 6.0) heated at 97 ºC for 20 minutes. Reactions were performed with REVEAL Biotin-Free Detection System (Spring Bioscience, CA) following manufacturer's instructions. Incubation with pan-VEGF antibody (MAB293, R and D Systems, MN) diluted 1:50 or VEGFA 165 b antibody (MAB3045, R and D Systems, MN) diluted 1:50 was performed overnight at 4ºC. Subsequently, the slides were washed with phosphate-buffered saline for 5 minutes and incubated with HRP conjugate and diaminobenzidine (DAB) as chromogen. The development time in DAB solution was 10 minutes. The slides were counterstained with Harris's hematoxylin for 40 seconds. Sections from mammary tumor tissue were used as positive control, and slides without primary antibody treatment were used as negative control. Images were obtained with a Camera Retiga 4000R (QImaging, CA) attached to an Olympus microscope (Model BX53, NY), and captured, averaged, and digitized using Image-Pro Plus 7.01 software (Media Cybernetics, USA). Illumination exposure was uniformly maintained and regularly checked in order to prevent any distortion of measurements (immunopositive area, gray level) among the samples. After capture, the image was analyzed using the software ImageJ, version 1.43m (Bethesda, USA) (Jensen et al., 2013) . After selection of the squamous cell region, the software calculated the immunopositive area by counting all pixels with gray intensity equal or superior to the threshold of staining. The threshold was defined for each protein evaluated, based on the mean immunopositivity of all control cases and taking into account the nuclear hematoxylin staining. Results were shown as a percentage of immunopositive area/total area. Three areas from each image were evaluated and the mean of percentage of immunopositivity was obtained for statistical analyses.
Statistical analyses
Statistical analyses were performed using the GraphPad Prism software version 5. 01 tissues (33.64% and 18.16%) (Figure 2 ).
Differential expression of VEGFA isoforms according to the anatomical sites
Analysis of expression in tumors compared to non-tumor tissues showed that VEGFA xxx was significantly overexpressed in pharynx tumors (p = 0.001). Overexpression of VEGFA xxx was also observed in larynx tumors (p = .035). VEGFA xxx expression differed significantly among the anatomical sites (p = 0.038), and the Post Test showed higher expression in the pharynx than oral tumors (Table 1 and Figure 3) . VEGFA 165 b showed significantly higher expression only in oral tumors as compared to non-tumor tissues (p = 0.0005) and presented differential expression among the anatomical sites (p = 0.02); the Post Test showed higher expression in oral tumor than in larynx tumor (Table 1 and Figure 4) . Regarding protein expression, there was no significant difference in expression of VEGFA xxx and VEGFA 165 b among the anatomical sites (p = 0.8473). 
Expression of VEGFA isoforms was not associated with tumor progression
Expression of SR splicing factors in HNSCC
SRSF1, SRSF5, SRSF6 and SRPK1 transcripts were detected in 52 tumor samples. SRSF5 presented higher expression in pharynx tumor as compared to non-tumor tissue (p = 0.003) and to the other anatomical sites (p = 0.033) ( Table 1) . SRPK1 was overexpressed in pharynx (p = 0.001) and larynx (p = 0.0009) tumors as compared to non-tumor tissue. SRPK1 presented differential expression among the anatomical sites (p < 0.0001), and the Post Test showed higher expression in pharynx and larynx tumors than in oral tumor (Table 1) . SRSF6 expression was lower in advanced tumors as compared to non-advanced tumors (p = 0.0339) ( Table 1) .
Correlation between the expression of VEGFA isoforms and SR proteins
VEGF165b presented positive correlation with SRSF1, SRSF5 and SRSF6 expression in tumors (Table 2) . No correlation was observed among SR factors and VEGFA xxx . Analysis of correlation between SR kinase SRPK1 and SR factors showed positive correlation with SRSF1 (r = 0.533, p < 0.0001), SRSF5 (r = 0.509, p = 0.002) and SRSF6 (r = 0.552, p < 0.0001) in tumor tissues.
Survival Analysis
The prognostic role of VEGFA xxx and VEGFA 165 b was evaluated by Kaplan-Meier survival analysis. Disease-free survival was defined as the time from surgical resection of the primary tumor to the tumor recurrence. Overall survival was defined as the time from surgical resection to the death or last follow-up. Patients were followed for a period of 48 months (median) and a maximum of 101 months. Fold change (FC) above the median was considered high expression of VEGFA xxx (FC = 1.5) and VEGFA 165 b (FC = 3.06) . The results showed that high expression of VEGFA xxx and VEGFA 165 b have no significant effect on disease-free survival or overall survival time (Table 3) .
Discussion
In the present study, VEGFA isoforms were overexpressed in HNSCC tumor samples as compared to non-tumor tissue. Overexpression of VEGFA is associated with tumor growth and results in increased angiogenesis (Das et al., 2007) . Anti-VEGFA drugs, as bevacizumab and sunitinib, are often used in the treatment of patients with cancer (Prager et al., 2010) . VEGFA overexpression have been found in solid tumors, such as breast cancer (Schneider et al., 2005) , colorectal tumor (Ferroni et al., 2006) and head and neck squamous cell carcinoma (Uehara et al., 2004 , Jaiswal et al., 2011 . For oral tumors, VEGFA expression was significantly associated with a poor prognosis (Uehara et al., 2004) . In bladder cancer, VEGFA protein was positively correlated with the tumor progression (Yang et al., 2015) .
In 2002 The expression of VEGFA isoforms was not associated with head and neck tumor progression in this study. Overexpression of total VEGFA in oral and pharynx advanced tumors (T3 and T4) has been observed in the presence of nodal metastasis (Boonkitticharoen et al., 2008) . High expression of total VEGFA was associated with larger tumor size, tumor progression and metastasis in larynx (Sullu et al., 2010) . However, regarding the antiangiogenic isoform, recent data have shown that VEGF xxx b was overexpressed in 97.3% of the pharynx and larynx tumor, independent of HPV status, but the expression was not associated with lymph node metastasis and survival (Wilkie et al., 2016) . These findings showed overexpression of VEGF xxx b in HNSCC, although it does not seem a reliable prognostic biomarker for tumors with presence of nodal metastasis, corroborating our results.
Analyzing the VEGFA isoforms expression data according to the tumor primary sites, we observed that pharynx tumors presented higher VEGFA xxx expression, and oral tumors presented higher VEGFA 165 b expression, reflecting the differential expression of these isoforms (Nowak et al., 2008; Slomiany et al., 2004) .
Concerning the splicing regulation of VEGFA isoforms by SR proteins, positive correlation was observed between gene expression of VEGFA 165 b isoform and all splicing factors, SRSF1, SRSF6 and SRSF5, in the present study. On the other hand, no correlation was found between the expression of SR proteins and VEGFA xxx . Although the effect of these splicing factors has been proposed by in vivo studies (Nowak et al., 2008; Nowak et al., 2010) the interaction between SR proteins and their target RNA at a specific site is influenced by several and multiple determining factors, such as competition with other SR proteins (Pandit et al., 2013) or other RNA binding proteins, including heterogeneous ribonucleoprotein proteins, and RNA secondary structure (Long et al., 2009) .
The expression of the SR kinase SRPK1 presented positive correlation with SRSF1, SRSF6 and SRSF5 in tumor tissues. These results suggest the co-expression of these splicing factors and the SR kinase SRPK1 and their involvement in VEGFA splicing. To date, it is known that SRPK1 phosphorylates SRSF1, but it can also phosphorylate other factors, including SRSF6. It is also known that other protein kinases like Clk1 are associated with the phosphorylation of SRSF1, SRSF6 and SRSF5. Further, SR proteins can be indirectly regulated by PKC and MAPK (Prasad et al., 1999; Lai et al. 2003) . Thus, other factors may contribute to the expression of these proteins in tumor samples.
In our point of view, the main finding was the overexpression of VEGFA 165 b in HNSCC as compared to non-tumor tissue. Importantly, there are no published studies investigating the gene expression pattern of VEGFA 165 b isoform in HNSCC. These results are important for the knowledge of the biology of head and neck cancer and may contribute to directing more effective therapeutic strategies in the treatment of these tumors. In addition, it is important to note that anti-VEGFA therapies currently used in cancer treatment target both the pro-and antiangiogenic isoforms, which could prevent the antiangiogenic activity of VEGFA xxx b isoforms in head and neck cancer, since this isoform is up regulated in this tumor type. Considering these issues, the use of therapy targeting only VEGFA xxx could improve the treatment outcomes in HNSCC (Carter et al., 2015) .
In summary, the results showed that VEGFA xxx and VEGFA 165 b are overexpressed in HNSCC development with possible contribution of SRSF1, SRSF6, SRSF5 and SRPK1 regulatory factors in alternative splicing of VEGFA gene. The findings contribute to the understanding of the role of VEGFA 165 b in cancer angiogenesis and increase the knowledge about the mechanism related to carcinogenesis development in head and neck.
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